INDIAN manufacturers are raising prices to pass on to consumers some of the burden of costlier energy and raw materials, which threatens to dent demand as well as a recovery from the Covid-19 pandemic, business leaders and economists say.
Prices of items from tea, coffee and biscuits to toothpaste and electric components have risen up to 10 per cent in the last quarter, while construction supplies, such as cement and sanitary ware, have added as much as a fifth, they said.
Big companies like Hindustan Unilever, Nestle, Procter & Gamble, Ambuja Cement and Kajaria Ceramics have blamed the increases on higher costs of oil and other raw materials.
As the economy swings into gear after pandemic curbs curtailed many activities over the last year, supply chain disruptions are also driving up prices.
"This is a challenge, as India's economic recovery is still not broad-based and the rising prices will hurt consumer sentiment," said Kapil Gupta, chief economist at Mumbai brokerage Edelweiss Securities.
After keeping above the central bank's target range of two per cent to six per cent, annual retail inflation eased in September to 4.35 per cent, helped by softening of food prices, which make up nearly half of the consumer price index.
But core inflation, excluding volatile prices of food and energy, has remained near six per cent for the last few months, reflecting the rising manufacturing prices.
Firms facing increases of 20-30 per cent in transport costs could raise prices further to maintain margins, say analysts, if the government offers no relief on energy costs.
Until now, prime minister Narendra Modi's administration has declined to cut fuel taxes that are the highest among the major economies, at more than 100 per cent of the base price.
Those building homes or renovating them to remedy defects made apparent during the pandemic-enforced curbs face a rise of more than 10 per cent in the cost of construction materials such as paint, cement and steel.
Kajaria Ceramics has raised the prices of its bathroom tiles by about seven per cent and sanitary ware by 10 per cent, while Asian Paints has hiked product prices by 7-10 per cent, analysts' reports showed.
"This time, the material increase has been fairly unnatural," said Amit Syngle, the chief executive of Asian Paints, warning that more hikes could be in store.
Consumer goods maker Hindustan Unilever, which markets more than 400 brands of food and beauty products, is struggling with the prices of palm oil, tea and crude and skyrocketing costs of shipping, said its chairman and managing director Sanjiv Mehta.
"The next few months will be critical to assess the underlying market demand and determine whether these are transient or structural," Mehta said after unveiling quarterly results last week.
Rural demand has slowed over the last two months, inspiring further caution, he added.
Private economists have warned that rising manufacturing and energy prices could dent the recovery from a record contraction of 7.3 per cent in the fiscal year that ended in March 2021.
Consumer spending, which contributes nearly 55 per cent of GDP, would be hurt by the rising prices, said Radhika Rao, a senior economist at DBS Bank.
"This might hold back consumption beyond the spurt on account of re-opening gains and festive demand, with employment gains yet to fully percolate to the unorganised sectors," she said, referring to celebrations around Diwali, the Hindu festival of lights.
Worried by rising prices, some private economists, including ratings agency Fitch, have cut growth forecasts to 8.7 per cent for the current fiscal year, down from nearly 10 per cent earlier.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.